WO2009016384A3 - Gsk-3 inhibitors - Google Patents

Gsk-3 inhibitors Download PDF

Info

Publication number
WO2009016384A3
WO2009016384A3 PCT/GB2008/002616 GB2008002616W WO2009016384A3 WO 2009016384 A3 WO2009016384 A3 WO 2009016384A3 GB 2008002616 W GB2008002616 W GB 2008002616W WO 2009016384 A3 WO2009016384 A3 WO 2009016384A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
peptide
seq
acid residues
independently
Prior art date
Application number
PCT/GB2008/002616
Other languages
French (fr)
Other versions
WO2009016384A2 (en
Inventor
Robert Martin Kypta
Original Assignee
Imp Innovations Ltd
Robert Martin Kypta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd, Robert Martin Kypta filed Critical Imp Innovations Ltd
Publication of WO2009016384A2 publication Critical patent/WO2009016384A2/en
Publication of WO2009016384A3 publication Critical patent/WO2009016384A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

A peptide inhibitor of glycogen synthase kinase-3 (GSK-3) comprising a peptide having between 6 and 50 amino acid residues and an amino acid sequence selected from PYYVNSGYA (SEQ ID No: 7), EPVNPYYVNSGYALAP (SEQ ID No: 6), and REPVNPYYVNSGYALAPATS (SEQ ID No: 5). A peptide inhibitor of GSK-3 comprising a peptide having between 13 and 50 amino acid residues and an amino acid sequence represented by the formula: EPXAZ1XBZ2XC(A/S)P (SEQ ID Nos: 54-61 ), wherein XA represents 2 or 3 amino acid residues which can, independently, be any amino acid residue, wherein XB represents 4 or preferably 5 amino acid residues which can, independently, be any amino acid residue, wherein Xc represents 1 or 2 amino acid residues which can, independently, be any amino acid residue, wherein Z1 and Z2, independently, represent Y, S or F and wherein (A/S) represents either A or S. The peptide is not phosphorylated at a tyrosine residue indicated by Y.
PCT/GB2008/002616 2007-08-01 2008-07-31 Gsk-3 inhibitors WO2009016384A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0714941.2A GB0714941D0 (en) 2007-08-01 2007-08-01 Inhibitors
GB0714941.2 2007-08-01

Publications (2)

Publication Number Publication Date
WO2009016384A2 WO2009016384A2 (en) 2009-02-05
WO2009016384A3 true WO2009016384A3 (en) 2009-04-09

Family

ID=38529084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002616 WO2009016384A2 (en) 2007-08-01 2008-07-31 Gsk-3 inhibitors

Country Status (2)

Country Link
GB (1) GB0714941D0 (en)
WO (1) WO2009016384A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010052137A1 (en) * 2000-03-01 2001-12-13 Trustees Of The University Of Pennsylvania Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling
WO2004108948A2 (en) * 2003-06-04 2004-12-16 President And Fellows Of Harvard College Systems, methods and kits for characterizing phosphoproteomes
WO2006018633A1 (en) * 2004-08-17 2006-02-23 Imperial Innovations Limited Use of gsk-3 inhibitors for the treatment of prostate cancer
WO2006054298A2 (en) * 2004-11-18 2006-05-26 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010052137A1 (en) * 2000-03-01 2001-12-13 Trustees Of The University Of Pennsylvania Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling
WO2004108948A2 (en) * 2003-06-04 2004-12-16 President And Fellows Of Harvard College Systems, methods and kits for characterizing phosphoproteomes
WO2006018633A1 (en) * 2004-08-17 2006-02-23 Imperial Innovations Limited Use of gsk-3 inhibitors for the treatment of prostate cancer
WO2006054298A2 (en) * 2004-11-18 2006-05-26 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors

Also Published As

Publication number Publication date
GB0714941D0 (en) 2007-09-12
WO2009016384A2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
TW200726842A (en) Mutant glucose dehydrogenase
WO2008019148A3 (en) Tumor suppression using placental stem cells
WO2006133426A3 (en) Compositions and methods for inhibition of the jak pathway
TW200710209A (en) Polishing composition
WO2007085895A3 (en) Fap inhibitors
WO2007023342A3 (en) Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof
WO2007079164A3 (en) Protein kinase inhibitors
UA101060C2 (en) Process fro the preparation of n-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
WO2008073687A3 (en) Compounds and compositions as protein kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
WO2008055068A8 (en) Inhibitors of histone deacetylase
NO20091291L (en) Solid citrate and tartrate salts of DPP-IV inhibitors
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
WO2008060476A3 (en) Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2008046919A3 (en) Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2012101599A3 (en) Glycogen synthase kinase-3 inhibitors
MX2009008449A (en) Process for preparing 2,6-dichloro-4-(trifluoromethyl)phenylhydra zine using mixtures of dichloro-fluoro-trifluoromethylbenzenes.
WO2008054215A3 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
WO2008054793A3 (en) Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
WO2009047992A1 (en) Udp-glucuronyl transferase and polynucleotide encoding the same
WO2005097799A8 (en) Pyrazolo`4,3-d! pyrimidines
WO2008066816A3 (en) Derivatization or ligaton of peptides
WO2005009951A3 (en) Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
EP1726655A4 (en) Beta fructofuranosidase mutant
TW200942602A (en) Polishing composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776106

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08776106

Country of ref document: EP

Kind code of ref document: A2